Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

NCT04170283 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

955

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Malignancies

Interventions

DRUG: Zanubrutinib
DRUG: Tislelizumab

Sponsor

BeiGene